Prevention of perioperative thromboembolism in patients with atrial fibrillation

British Journal of Surgery

Volumn 94, Issue 11, 2007, Pages 1351-1355

  Beldi, G ^a   Beng, L ^a   Siegel, G ^a   Bisch Knaden, S ^a   Candinas, D ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; AGED; ANTICOAGULATION; BLEEDING; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DATA BASE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; PEROPERATIVE COMPLICATION; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE; SURGICAL MORTALITY; SURGICAL TECHNIQUE; THROMBIN TIME; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 36348998071     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5835     Document Type: Review

References (24)

1. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-1511.
2. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
3. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
4. Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet 2006; 367: 262-272.
5. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2003; 163: 901-908.
6. Ansell JE. The perioperative management of warfarin therapy. Arch Intern Med 2003; 163: 881-883.
7. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164: 1319-1326.
8. Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AGG, Bates SM et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110: 1658-1663.
9. Torn M, Bollen WLEM, van der Meer FJM, van der Wall EE, Rosendaal FR. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005; 165: 1527-1532.
10. Bonow RO, Carabello B, de Leon AC, Edmunds LH Jr, Fedderly BJ, Freed MD et al. ACC/AHA guidelines for the management of patients with valvular heart disease. Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Heart Valve Dis 1998; 7: 672-707.
11. Hall DL, Steen WH Jr, Drummond JW, Byrd WA. Anticoagulants and cataract surgery. Ophthalmic Surg 1988; 19: 221-222.
12. Poller L, Thomson J. Evidence for 'rebound' hypercoagulability after stopping anticoagulants. Lancet 1964; 39: 62-64.
13. Genewein U, Haeberli A, Straub PW, Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996; 92: 479-485.
14. Kikura M, Takada T, Sato S. Preexisting morbidity as an independent risk factor for perioperative acute thromboembolism syndrome. Arch Surg 2005; 140: 1210-1217.
15. Tinmouth AH, Morrow BH, Cruickshank MK, Moore PM, Kovacs MJ. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother 2001; 35: 669-674.
16. Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999; 84: 478-480, A410.
17. Horne MK III, Chao ES. The effect of molecular weight on heparin binding to platelets. Br J Haematol 1990; 74: 306-312.
18. Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann N Y Acad Sci 1989; 556: 245-254.
19. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245.
20. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73.
21. Counsell C, Sandercock P. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review). Stroke 2002; 33: 1925-1926.
22. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004; (4)CD001100.
23. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004; 140: 175-183.
24. Sandercock P, Counsell C, Stobbs SL. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev 2005; (2)CD000119.